A Prospective Randomized Trial to Study the Impact of Pretreatment FDG-PET for Cervical Cancer Patients With MRI-Detected Positive Pelvic but Negative Para-Aortic Lymphadenopathy

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 2, 2010, Pages 477-484

  Tsai, Chien Sheng ^a,b   Lai, Chyong Huey ^a   Chang, Ting Chang ^a   Yen, Tzu Chen ^a   Ng, Koon Kwan ^a   Hsueh, Swei ^a   Lee, Steve P ^c   Hong, Ji Hong ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Cervical cancer; Extended field radiotherapy; Extrapelvic metastasis; Positive pelvic node

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; AFTER-TREATMENT; CERVICAL CANCER; CERVICAL CANCERS; CONCURRENT CHEMORADIOTHERAPY; CONTROL GROUPS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FDG-PET; IRRADIATION FIELDS; LYMPH NODE; LYMPHADENOPATHY; MAGNETIC RESONANCE IMAGES; MRI IMAGE; OVERALL SURVIVAL; PELVIC NODES; PERFORMANCE STATUS; PRE-TREATMENT; PROSPECTIVE RANDOMIZED TRIAL; RADIATION FIELD; STUDY GROUPS;

BLOOD VESSELS; CHEMICAL MODIFICATION; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRONS; RADIOTHERAPY;

POSITRON EMISSION TOMOGRAPHY;

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTUM; OPEN STUDY; OVERALL SURVIVAL; PARAORTIC LYMPHADENOPATHY; PELVIS LYMPH NODE; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AORTA; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PELVIS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; UTERINE CERVICAL NEOPLASMS;

EID: 73649132953     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.020     Document Type: Article

References (36)

1. Hong J.H., Tsai C.S., Chang J.T., et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 41 (1998) 823-830
2. Hong J.H., Tsai C.S., Lai C.H., et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 63 (2005) 492-499
3. Kapp K.S., Stuecklschweiger G.F., Kapp D.S., et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 42 (1998) 531-540
4. Toita T., Kakinohana Y., Shinzato S., et al. Tumor diameter/volume and pelvic node status assessed by magnetic resonance imaging (MRI) for uterine cervical cancer treated with irradiation. Int J Radiat Oncol Biol Phys 43 (1999) 777-782
5. Barillot I., Horiot J.C., Pigneux J., et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: A French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys 38 (1997) 969-978
6. Tsai C.S., Lai C.H., Wang C.C., et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol 75 (1999) 328-333
7. Chatani M., Matayoshi Y., Masaki N., et al. Prophylactic irradiation of para-aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlenther Onkol 171 (1995) 655-660
8. Haie C., Pejovic M.H., Gerbaulet A., et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 11 (1988) 101-112
9. Rotman M., Pajak T.F., Choi K., et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 274 (1995) 387-393
10. Grigsby P.W., Heydon K., Mutch D.G., et al. Long-term follow-up of RTOG 92-10: Cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 51 (2001) 982-987
11. Small Jr. W., Winter K., Levenback C., et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 68 (2007) 1081-1087
12. Rose P.G., Adler L.P., Rodriguez M., et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study. J Clin Oncol 17 (1999) 41-45
13. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 218 (2001) 776-782
14. Lin W.C., Hung Y.C., Yeh L.S., et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 89 (2003) 73-76
15. Sironi S., Buda A., Picchio M., et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: Detection with integrated FDG PET/CT. Radiology 238 (2006) 272-279
16. Grigsby P.W., Siegel B.A., and Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19 (2001) 3745-3749
17. Tsai C.S., Chang T.C., Lai C.H., et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys 58 (2004) 1506-1512
18. Chang T.C., Law K.S., Hong J.H., et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 101 (2004) 164-171
19. Yen T.C., Ng K.K., Ma S.Y., et al. Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 21 (2003) 3651-3658
20. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Hong J., Tsai C., Chang T., et al. An interim analysis of a phase III randomized trial of using FDG-PET in the management of cervical cancer patients with positive pelvic node on MRI image. Int J Radiat Oncol Biol Phys 66 Suppl (2006) S163
22. Miller T.R., and Grigsby P.W. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 53 (2002) 353-359
23. Ma S.-Y., See L.-C., Lai C.-H., et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 44 (2003) 1775-1783
24. Lin L.L., Mutic S., Low D.A., et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys 67 (2007) 91-96
25. Lin L.L., Yang Z., Mutic S., et al. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys 65 (2006) 177-181
26. Grigsby P.W., Siegel B.A., Dehdashti F., et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome. J Clin Oncol 22 (2004) 2167-2171
27. Schwarz J.K., Siegel B.A., Dehdashti F., et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298 (2007) 2289-2295
28. Carey B.P., Coleman R.E., Grigsby P.W., et al. Medicare coverage of PET for cervical cancer. J Am Coll Radiol 3 (2006) 19-22
29. Boffetta P., and Parkin D.M. Cancer in developing countries. CA Cancer J Clin 44 (1994) 81-90
30. Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 Suppl 1 (2006) S205-S210
31. Grigsby P.W., Singh A.K., Siegel B.A., et al. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys 59 (2004) 706-712
32. Grigsby P.W., Mutch D.G., Rader J., et al. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys 61 (2005) 444-449
33. Lai C.H., Huang K.G., Hong J.H., et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol 89 (2003) 160-167
34. Choi H.J., Roh J.W., Seo S.S., et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: A prospective study. Cancer 106 (2006) 914-922
35. Wright J.D., Dehdashti F., Herzog T.J., et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 104 (2005) 2484-2491
36. Loft A., Berthelsen A.K., Roed H., et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. Gynecol Oncol 106 (2007) 29-34